The company is positioned in home care and chronic disease management fields. With diversified medical device portfolio spanning respiratory, diagnostic, and rehabilitation categories, Yuyue leverages manufacturing expertise and broad distribution to capture growth in aging demographics and rising healthcare demand across Asia-Pacific regions.
Cyborg Score Rationale
With 2024 revenue of $1.1B (down 5.1% YoY) and a market cap of $5.7B, the company faces near-term headwinds from declining revenue and a 24.6% drop in net income, but maintains substantial scale with 6,346 employees. The diverse product portfolio and international presence provide resilience, though recent financial contraction warrants monitoring.
Top Insights
Core strength in respiratory and home care devices positions company well for aging population trends in China
2024 financial decline (revenue -5.1%, net income -24.6%) indicates competitive or demand pressures requiring operational improvement
Diversified product portfolio across 5+ medical device categories reduces single-product dependency
International distribution capability provides growth optionality beyond domestic Chinese market
Named Competitors
Respiratory Care Products — Respiratory and home care solutions
Medical Diagnostic Devices — Blood pressure monitors and health monitoring
Home Medical Equipment — PAP therapy and respiratory devices
Open the full interactive Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.